• Affordable Educational Credits
  • Watch At Your Convenience
  • Worldwide Speakers
  • Captivating Topics
  • Peer Interactions
Watch Today!
View Lecture
Note: Currently only available through a bundled series of lectures

Domperidone and Breastfeeding

by Dr. Frank Nice, RPh, DPA,CPHP
  • Duration: 60 Mins
  • Credits: 1 CERP, 1 L-CERP
  • Learning Format: Webinar
  • Handout: Yes
  • Origin: GOLD Lactation 2014

Domperidone currently is used worldwide as an anti-nausea agent for adults, children, and women. It is currently available in 60 countries including Canada and Mexico. Domperidone was recently given orphan drug designation for the treatment of hypoprolactinemia in breastfeeding. Over 60,000 cases of hypoprolactinemia are reported annual in the United States. Infants who do not receive human milk cost the healthcare system over $13 billion each year and result in over 900 unnecessary infant deaths annually. Domperidone can produce significant increases in prolactin with subsequent increases in milk production. No drug is currently approved for the condition of hypoprolactinemia of lactation in any country.

This presentation will describe and explain the Orphan Drug Act and the steps necessary for domperidone to receive approval under the Act. Prolactin facts will be discussed as well as a review of the rare disease, hypoprolactinemia. The scientific rationale for the use of domperidone will be covered. Practical information will be presented on domperidone dosing and withdrawal of the drug with sufficient milk supply and with insufficient milk supply.

Learning Objectives:

Objective 1: Explain the orphan drug process for domperidone and describe the rare disease, hyoprolactinemia
Objective 2: Understand the scientific and clinical rational for the use of domperidone
Objective 3: counsel breastfeeding mothers on the use of domperidone

Categories: Managing Milk Supply,
Presentations: 28  |  Hours / CE Credits: 23.25  |  Viewing Time: 8 Weeks